Skip to Header





Skip Menu

Stroke Clinical Trials at OhioHealth

Pioneering Stroke Treatments and Technologies

WE are a nationwide leader in research through our active participation in stroke clinical trials.

Because of the high volume of stroke patients we treat, OhioHealth Neuroscience Center at Riverside Methodist Hospital is able to pioneer leading-edge treatments and technologies through active participation in clinical trials. 

Stroke Clinical Trials at OhioHealth

Below are the stroke clinical trials in which we’re currently actively involved: 


Analysis of Revascularization in Ischemic Stroke With EmboTrap (ARISE II)

The purpose of this study is to examine the safety and efficacy of the EmboTrap device in treating acute ischemic stroke patients who are found to have a large artery occlusion per neurodiagnostic imaging.

Learn more at


Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)

The purpose of this study is to validate the clinical use of new biomarker blood tests to identify blood components that may differentiate between diverse stroke etiologies and clinical outcomes.

Learn more at


Trevo and Medical Management Versus Medical Management Alone in Wake Up and Late Presenting Strokes (DAWN)

The purpose of this study is to evaluate the hypothesis that Trevo thrombectomy plus medical management leads to superior clinical outcomes at 90 days as compared to medical management alone in appropriately selected subjects experiencing an acute ischemic stroke when treatment is initiated within 6-24 hours after last seen well.

Learn more at


POSITIVE Stroke Clinical Trial

The primary objective of this randomized trial is to determine the safety and efficacy of intra-arterial reperfusion in Acute Ischemic Stroke (AIS) patients ineligible for IV-tPA as selected by physiologic imaging criteria.

Learn more at


A Study of the Efficacy and Safety of Activase (Alteplase) in Patients With Mild Stroke (PRISMS) 

This double-blind, randomized study is to evaluate the efficacy and safety of intravenous (IV) Activase in patients with mild acute ischemic strokes that do not appear to be clearly disabling. Patients will be randomized in a 1:1 ratio either 1) one dose of IV Activase and one dose of oral aspirin placebo or 2) one dose of IV Activase placebo and one dose of oral aspirin 325 mg. Treatment must be able to be initiated within 3 hours of last known well time.

Learn more at


Optimizing Patient’s Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT)

This is an observational study acquiring imaging and clinical variables known to affect clinical outcomes after endovascular therapy in an effort to evaluate and compare the different selection methods and criteria currently used in practice for acute ischemic stroke patients with large vessel occlusions in the anterior circulation. The study aim is to evaluate different methodologies, to compare them against each other to identify which method provides the highest predictive ability and to develop a formula that predicts patient outcomes.

Learn more at

Trevo Registry

Trevo® Retriever Registry Post Market Surveillance 

The purpose of the Trevo® Retriever Registry is to collect real-world performance data of the Trevo Retriever, which is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke.

Learn more at


Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) Protocol

A set of two multicenter randomized trials that run in parallel – CEA in addition to intensive medical management (IMM) vs. intensive medical management alone OR CAS + IMM vs. IMM alone.

Learn more at


CREST 2 Registry (C2R)

A companion study to accompany CREST-2, this registry is for expansion of Medicare coverage for CAS to include procedures performed as part of C2R on symptomatic and asymptomatic patients beyond those categories covered under the 2005 CMS decision. Patients must either be excluded from or decline randomized trial CREST-2. 

Learn more at